Historique de carrière de Denis G. Bosc
Anciens postes connus de Denis G. Bosc
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| NERVGEN PHARMA CORP. | Corporate Officer/Principal | 30/05/2019 | 01/04/2020 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 17/01/2011 | 01/10/2012 |
| SQI DIAGNOSTICS INC. | Corporate Officer/Principal | 10/08/2009 | 01/08/2010 |
Viventia Biotech, Inc.
 Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Corporate Officer/Principal | 01/01/2007 | 01/08/2008 |
Formation de Denis G. Bosc
| University of Manitoba | Doctorate Degree |
Statistiques
Internationale
| Canada | 5 |
| Royaume-Uni | 2 |
Opérationnelle
| Corporate Officer/Principal | 4 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SQI DIAGNOSTICS INC. | Health Technology |
| NERVGEN PHARMA CORP. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
- Bourse
- Insiders
- Denis G. Bosc
- Expérience
